Low molecular weight heparin suppresses lymphatic endothelial cell proliferation induced by vascular endothelial growth factor C in vitro
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 13
- DOI:
- 10.3760/cma.j.issn.0366-6999.2009.13.018
- Key Word:
- low molecular weight heparin;vascular endothelial growth factor C;human lymphatic endothelial cell;pancreatic cancer cell;proliferation
Abstract： Background Pancreatic cancer is one of the most aggressive human malignancies. Lymphangiogenesis plays an important role in lymph node metastasis of many solid tumors. It is well known that low molecular weight heparins (LMWHs) can inhibit cell growth, cell invasion and angiogenesis, which are key processes in tumor progression. Methods We measured the expression of vascular endothelial growth factor C (VEGF-C) in pancreatic cancer cells (PANC-1) using reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. We used an in vitroassay to evaluate the anti-lymphangiogenic effect of an LMWH, Fragmin, on human lymphatic endothelial cell (HLEC) proliferation. Results Fragmin at a low concentration can effectively inhibits HLEC proliferation induced by VEGF-C. VEGF-C secreted by PANC-1 cells stimulated HLEC proliferation. Low concentration LMWH suppressed HLEC proliferation induced by VEGF-C but did not affect proliferation or VEGF-C expression of PANC-1 cells, whereas high concentrations of LMWH inhibited PANC-1 cell proliferation. Conclusions These results suggest that VEGF-C released by cancer cells plays an important role in promoting HLEC proliferation. The LMWH Fragmin has anti-lymphangiogenic effects and may inhibit lymphatic metastasis in pancreatic cancer.
- [1].Molecular Control of Lymphatic Metastasis[J].2008,1131.
- [2]J, Fareed,D A, Hoppensteadt,R L, Bick.An update on heparins at the beginning of the new millennium.[J].2000,26 Suppl 1.
- [3]Bernard Lebeau M.D.,Claude Chastang M.D., Ph.D.,Jeanne-Marie Brechot M.D.,etc.Subcutaneous heparin treatment increases survival in small cell lung cancer[J].1994,74(1).
- [4]Korc M,Buchler MW,Kleeff J,etc.Molecular aspects of pancreatic cancer and future perspectives.[J].1999,16(4).
- [5]Steven A, Stacker,Marc G, Achen,Lotta, Jussila,etc.Lymphangiogenesis and cancer metastasis.[J].2002,2(8).
- [6]Boiardi A,Marras C,Croci D,etc.In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.[J].2006,16(5).
- [7]Kamata S,Miyazaki M,Kishimoto T,etc.Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.[J].2007,98(5).
- [8]Mousa SA,Mohamed S.Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.[J].2004,92(3).
- [9]mc.uva.nl,Van-Noorden CJ,Smorenburg SM.The complex effects of heparins on cancer progression and metastasis in experimental studies.[J].2001,53(1).
- [10]Bros A.,Matou S.,Letourneur D.,etc.Modulation of human endothelial coil proliferation and migration byfucoidan and heparin[J].1998,77(4).
- [11]Wilting J,Giese T,Giese N,etc.Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread.[J].2006,28(4).
- [12]van Hinsbergh VW,Kaipainen A,Dumont D,etc.Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.[J].1995,92(8).